Actively Recruiting
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-11-18
460
Participants Needed
1
Research Sites
266 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.
CONDITIONS
Official Title
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary participation and written informed consent
- Age 18 to 75 years, any gender
- Newly diagnosed, histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer that has not received prior treatment
- Confirmed tumor PD-L1 status before randomization
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 3 months
- At least one measurable lesion according to RECIST v1.1
You will not qualify if you...
- Untreated central nervous system metastasis, meningeal metastasis, or spinal cord compression
- Uncontrolled symptomatic pleural effusion, pericardial effusion, or ascites
- Previous or co-existing malignancies
- Active or prior autoimmune or inflammatory disorders
- Active hepatitis B or C infection, or history of immunodeficiency
- Active or past history of interstitial lung disease or pneumonitis, including drug-induced or radiation-related
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China, 250117
Actively Recruiting
Research Team
W
Weixia Li
CONTACT
Y
Yang Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here